Anti-Aβ single-chain variable fragment antibodies exert synergistic neuroprotective activities in Drosophila models of Alzheimer's disease

Human Molecular Genetics

Volumn 24, Issue 21, 2015, Pages 6093-6105

  Fernandez Funez, Pedro ^a,b   Zhang, Yan ^a   Sanchez Garcia, Jonatan ^a   de Mena, Lorena ^a   Khare, Swati ^a   Golde, Todd E ^a,b   Levites, Yona ^b   Rincon Limas, Diego E ^a,b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; EPITOPE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY 42.2; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY 9; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

ADULT; ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; CARBOXY TERMINAL SEQUENCE; CELL DEATH; CELL STRUCTURE; CONTROLLED STUDY; DENDRITE; DROSOPHILA; DRUG EFFECT; DRUG POTENTIATION; DRUG PROTEIN BINDING; EYE TOXICITY; FEMALE; FRUIT FLY MODEL; LOCOMOTION; MALE; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; COMPOUND EYE; DISEASE MODEL; IMMUNOLOGY; METABOLISM; MOTOR ACTIVITY; NERVE CELL; PATHOLOGY; PRECLINICAL STUDY; PROCEDURES; TRANSGENIC ANIMAL;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANIMALS, GENETICALLY MODIFIED; BRAIN; COMPOUND EYE, ARTHROPOD; DISEASE MODELS, ANIMAL; DROSOPHILA; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; FEMALE; MALE; MOTOR ACTIVITY; NEURONS; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; SINGLE-CHAIN ANTIBODIES;

EID: 84949233665     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddv321     Document Type: Article

References (40)

1. Overk, C.R. and Masliah, E. (2014) Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease. Biochem. Pharmacol., 88, 508-516.
2. Hardy, J.A. and Higgins, G.A. (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science, 256, 184-185.
3. Hardy, J. (2009) The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J. Neurochem., 110, 1129-1134.
4. Benilova, I., Karran, E. and De Strooper, B. (2012) The toxic Abeta oligomer and Alzheimer's disease: an emperor in need of clothes. Nat. Neurosci., 15, 349-357.
5. Wisniewski, T. and Goni, F. (2014) Immunotherapy for Alzheimer's disease. Biochem. Pharmacol., 88, 499-507.
6. Spencer, B. and Masliah, E. (2014) Immunotherapy for Alzheimer's disease: past, present and future. Front. Aging Neurosci., 6, 114.
7. Gilman, S., Koller, M., Black, R.S., Jenkins, L., Griffith, S.G., Fox, N.C., Eisner, L., Kirby, L., Rovira, M.B., Forette, F. et al. (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology, 64, 1553-1562.
8. Orgogozo, J.M., Gilman, S., Dartigues, J.F., Laurent, B., Puel, M., Kirby, L.C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S. et al. (2003) Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology, 61, 46-54.
9. Golde, T.E. (2014) Open questions for Alzheimer's disease immunotherapy. Alzheimers Res. Ther., 6, 3.
10. Barakos, J., Sperling, R., Salloway, S., Jack, C., Gass, A., Fiebach, J.B., Tampieri, D., Melancon, D., Miaux, Y., Rippon, G. et al. (2013) MR imaging features of amyloid-related imaging abnormalities. AJNR, 34, 1958-1965.
11. Sperling, R., Salloway, S., Brooks, D.J., Tampieri, D., Barakos, J., Fox, N.C., Raskind, M., Sabbagh, M., Honig, L.S., Porsteinsson, A.P. et al. (2012) Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet. Neurol., 11, 241-249.
12. Salloway, S., Sperling, R., Fox, N.C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L.S., Porsteinsson, A.P., Ferris, S. et al. (2014) Two phase 3 trials of bapineuzumab in mildto- moderate Alzheimer's disease. N. Engl. J. Med., 370, 322-333.
13. Doody, R.S., Thomas, R.G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P.S. et al. (2014) Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N. Engl. J. Med., 370, 311-321.
14. Robert, R. and Wark, K.L. (2012) Engineered antibody approaches for Alzheimer's disease immunotherapy. Arch. Biochem. Biophys., 526, 132-138.
15. Frenkel, D., Solomon, B. and Benhar, I. (2000) Modulation of Alzheimer's beta-amyloid neurotoxicity by site-directed single-chain antibody. J. Neuroimmunol., 106, 23-31.
16. Liu, R., Yuan, B., Emadi, S., Zameer, A., Schulz, P., McAllister, C., Lyubchenko, Y., Goud, G. and Sierks, M.R. (2004) Single chain variable fragments against beta-amyloid (Abeta) caninhibit Abeta aggregation and prevent abeta-induced neurotoxicity. Biochemistry, 43, 6959-6967.
17. Wang, X.P., Zhang, J.H., Wang, Y.J., Feng, Y., Zhang, X., Sun, X.X., Li, J.L., Du, X.T., Lambert, M.P., Yang, S.G. et al. (2009) Conformation- dependent single-chain variable fragment antibodies specifically recognize beta-amyloid oligomers. FEBS Lett., 583, 579-584.
18. Levites, Y., Jansen, K., Smithson, L.A., Dakin, R., Holloway, V.M., Das, P. and Golde, T.E. (2006) Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice. J. Neurosci., 26, 11923-11928.
19. Meli, G., Visintin, M., Cannistraci, I. and Cattaneo, A. (2009) Direct in vivo intracellular selection of conformation-sensitive antibody domains targeting Alzheimer's amyloid-beta oligomers. J. Mol. Biol., 387, 584-606.
20. Fukuchi, K., Accavitti-Loper, M.A., Kim, H.D., Tahara, K., Cao, Y., Lewis, T.L., Caughey, R.C., Kim, H. and Lalonde, R. (2006) Amelioration of amyloid load by anti-Abeta single-chain antibody in Alzheimer mouse model. Biochem. Biophys. Res. Commun., 344, 79-86.
21. Fukuchi, K., Tahara, K., Kim, H.D., Maxwell, J.A., Lewis, T.L., Accavitti-Loper, M.A., Kim, H., Ponnazhagan, S. and Lalonde, R. (2006) Anti-Abeta single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease. Neurobiol. Dis., 23, 502-511.
22. Ryan, D.A., Mastrangelo, M.A., Narrow, W.C., Sullivan, M.A., Federoff, H.J. and Bowers, W.J. (2010) Abeta-directed singlechain antibody delivery via a serotype-1 AAV vector improves learning behavior and pathology in Alzheimer's disease mice. Mol. Ther., 18, 1471-1481.
23. Gimenez-Llort, L., Rivera-Hernandez, G., Marin-Argany, M., Sanchez-Quesada, J.L. and Villegas, S. (2013) Early intervention in the 3xTg-AD mice with an amyloid beta-antibody fragment ameliorates first hallmarks of Alzheimer disease. mAbs, 5, 665-677.
24. Frenkel, D. and Solomon, B. (2002) Filamentous phage as vector-mediated antibody delivery to the brain. Proc. Natl Acad. Sci. USA, 99, 5675-5679.
25. Yang, J., Pattanayak, A., Song, M., Kou, J., Taguchi, H., Paul, S., Ponnazhagan, S., Lalonde, R. and Fukuchi, K. (2013) Muscledirected anti-Abeta single-chain antibody delivery via AAV1 reduces cerebral Abeta load in an Alzheimer's disease mouse model. J. Mol. Neurosci., 49, 277-288.
26. Cattepoel, S., Hanenberg, M., Kulic, L. and Nitsch, R.M. (2011) Chronic intranasal treatment with an anti-Abeta(30-42) scFv antibody ameliorates amyloid pathology in a transgenic mouse model of Alzheimer's disease. PLoS One, 6, e18296.
27. Casas-Tinto, S., Zhang, Y., Sanchez-Garcia, J., Gomez-Velazquez, M., Rincon-Limas, D.E. and Fernandez-Funez, P. (2011) The ER stress factor XBP1s prevents amyloid-beta neurotoxicity. Hum. Mol. Genet., 20, 2144-2160.
28. Greeve, I., Kretzschmar, D., Tschape, J.A., Beyn, A., Brellinger, C., Schweizer, M., Nitsch, R.M. and Reifegerste, R. (2004) Agedependent neurodegeneration and Alzheimer-amyloid plaque formation in transgenic Drosophila. J. Neurosci., 24, 3899-3906.
29. Davis, R.L. (2005) Olfactory memory formation in Drosophila: frommolecular to systems neuroscience. Annu. Rev. Neurosci., 28, 275-302.
30. Tanaka, N.K., Tanimoto, H. and Ito, K. (2008) Neuronal assemblies of the Drosophila mushroom body. J. Comp. Neurol., 508, 711-755.
31. Wolfgang, W.J., Miller, T.W., Webster, J.M., Huston, J.S., Thompson, L.M., Marsh, J.L. and Messer, A. (2005) Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies. Proc. Natl Acad. Sci. USA, 102, 11563-11568.
32. Wacker, J., Ronicke, R., Westermann, M., Wulff, M., Reymann, K.G., Dobson, C.M., Horn, U., Crowther, D.C., Luheshi, L.M. and Fandrich, M. (2014) Oligomer-targeting with a conformational antibody fragment promotes toxicity in Abeta-expressing flies. Acta Neuropathol. Commun., 2, 43.
33. Groth, A.C., Fish, M., Nusse, R. and Calos, M.P. (2004) Construction of transgenic Drosophila by using the sitespecific integrase from phage phiC31. Genetics, 166, 1775-1782.
34. Levites, Y., Smithson, L.A., Price, R.W., Dakin, R.S., Yuan, B., Sierks, M.R., Kim, J., McGowan, E., Reed, D.K., Rosenberry, T.L. et al. (2006) Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer's disease mouse models. FASEB J., 20, 2576-2578.
35. Liu, Y.H., Giunta, B., Zhou, H.D., Tan, J. and Wang, Y.J. (2012) Immunotherapy for Alzheimer disease: the challenge of adverse effects. Nat. Rev. Neurol., 8, 465-469.
36. Brand, A.H. and Perrimon, N. (1993) Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development, 118, 401-415.
37. Rubin, G.M. and Spradling, A.C. (1982) Genetic transformation of Drosophila with transposable element vectors. Science, 218, 348-353.
38. Rincon-Limas, D.E., Lu, C.H., Canal, I. and Botas, J. (2000) The level of DLDB/CHIP controls the activity of the LIM homeodomain protein apterous: evidence for a functional tetramer complex in vivo. Embo J., 19, 2602-2614.
39. Fernandez-Funez, P., Casas-Tinto, S., Zhang, Y., Gomez-Velazquez, M., Morales-Garza, M.A., Cepeda-Nieto, A.C., Castilla, J., Soto, C. and Rincon-Limas, D.E. (2009) In vivo generation of neurotoxic prion protein: role for hsp70 in accumulation of misfolded isoforms. PLoS Genet., 5, e1000507.
40. Kim, J., Miller, V.M., Levites, Y., West, K.J., Zwizinski, C.W., Moore, B.D., Troendle, F.J., Bann, M., Verbeeck, C., Price, R.W. et al. (2008) BRI2 (ITM2b) inhibits Abeta deposition in vivo. J. Neurosci., 28, 6030-6036.